First-in-human studies by our group demonstrated that our polymer-based tissue engineered vascular grafts (TEVGs) represent an exciting new treatment option for children afflicted with congenital heart disease. In particular, the natural evolution of these grafts from a biodegradable tubular scaffold seeded with autologous cells to a neovessel consisting of native cells and extracellular matrix represents the first graft with true ?growth potential?, which could eliminate problems associated with somatic overgrowth, the process by which patients outgrow their graft. Nevertheless, widespread clinical adaptation of these TEVGs to treat children with congenital heart disease has been slowed by a high incidence of ?stenosis? even though angioplasty can be used to safely manage this complication. Recent findings from our group suggest, however, that the observed early narrowing of the TEVG that has been interpreted as stenosis may actually resolve naturally and simply be a part of its normal natural history, thus rendering angioplasty not needed or even ill advised. There is a pressing need to understand better the natural history of neovessel formation. Toward this end, we developed a large animal (sheep) model wherein implanted TEVGs phenocopy human grafts, that is, some develop a narrowing while others do not. We submit that (i) this animal model can provide longitudinal data (in vivo geometric & hemodynamic, in vitro biomechanical, and cell biological & histological) that are needed to build a novel computational model of TEVG development and (ii) such a computational model can provide unique insight into the natural history of TEVG development as well as a predictive capability that will enable better informed decisions regarding potential interventional treatment (angioplasty) during TEVG development. To this end, our proposed ?fluid-solid-growth? model will integrate validated subject-specific fluid-solid interaction and vascular growth and remodeling simulations in three dimensions to quantify the natural history of TEVG development in vivo, including potential narrowing and the need to treat with angioplasty or not. The model will be informed and validated using in vivo sheep data, and its predictive capability verified in prospective model-guided angioplasty procedures. The resulting computational framework will enable the first three-dimensional, subject-specific fluid-solid-growth vascular simulations, which will improve the use and future design of TEVGs for congenital surgery as well as have broad utility for predicting disease progression in diverse cardiovascular applications that are driven by immuno- or mechano-biological mechanisms. This work will be accomplished by bringing together expertise from three complementary groups, having a track record of prior accomplishments, to advance the use of a promising technology that has the potential to impact significantly the well being of those afflicted with congenital cardiac anomalies.

Public Health Relevance

Congenital cardiac anomalies represent the most common birth defect, affecting nearly 1% of all live births. Despite significant advances in surgical and medical management, these conditions remain a leading cause of death and disability in the newborn period. In this project, we will develop a data-driven computational model that can enhance the performance of a novel class of tissue engineered vascular grafts specifically designed to improve the outcomes of congenital heart surgery in children.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL139796-04
Application #
10082302
Study Section
Modeling and Analysis of Biological Systems Study Section (MABS)
Program Officer
Lundberg, Martha
Project Start
2018-01-01
Project End
2021-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
4
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Fukunishi, Takuma; Best, Cameron A; Ong, Chin Siang et al. (2018) Role of Bone Marrow Mononuclear Cell Seeding for Nanofiber Vascular Grafts. Tissue Eng Part A 24:135-144
Stacy, Mitchel R; Best, Cameron A; Maxfield, Mark W et al. (2018) Magnetic Resonance Imaging of Shear Stress and Wall Thickness in Tissue-Engineered Vascular Grafts. Tissue Eng Part C Methods 24:465-473
Best, Cameron; Fukunishi, Takuma; Drews, Joseph et al. (2018) Oversized Biodegradable Arterial Grafts Promote Enhanced Neointimal Tissue Formation. Tissue Eng Part A 24:1251-1261
Liu, Ju; Marsden, Alison L (2018) A unified continuum and variational multiscale formulation for fluids, solids, and fluid-structure interaction. Comput Methods Appl Mech Eng 337:549-597
Miyachi, Hideki; Reinhardt, James W; Otsuru, Satoru et al. (2018) Bone marrow-derived mononuclear cell seeded bioresorbable vascular graft improves acute graft patency by inhibiting thrombus formation via platelet adhesion. Int J Cardiol 266:61-66
B Ramachandra, Abhay; Humphrey, Jay D (2018) Biomechanical characterization of murine pulmonary arteries. J Biomech :
Szafron, J M; Khosravi, R; Reinhardt, J et al. (2018) Immuno-driven and Mechano-mediated Neotissue Formation in Tissue Engineered Vascular Grafts. Ann Biomed Eng 46:1938-1950
Onwuka, Ekene; King, Nakesha; Heuer, Eric et al. (2018) The Heart and Great Vessels. Cold Spring Harb Perspect Med 8:
Best, Cameron; Strouse, Robert; Hor, Kan et al. (2018) Toward a patient-specific tissue engineered vascular graft. J Tissue Eng 9:2041731418764709
Szafron, Jason M; Breuer, Christopher K; Wang, Yadong et al. (2017) Stress Analysis-Driven Design of Bilayered Scaffolds for Tissue-Engineered Vascular Grafts. J Biomech Eng 139:

Showing the most recent 10 out of 11 publications